The regulation-common law feedback loop in nonpreemptive regimes

Preemption Choice: The Theory, Law, and Reality of Federalism's Core Question

Volumn , Issue , 2008, Pages 235-256

  McGarity, Thomas O ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF LAW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927030870     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511552007.012     Document Type: Chapter

References (70)

1. St. Paul, MN: American Law Institute, 2000.
2. David G. Owen, Products Liability Law (St. Paul, MN: West, 2005), 93.
3. Robert L. Rabin, “Reassessing Regulatory Compliance,” Georgetown Law Journal, 88, no. 6 (2000): 2051.
4. Lars Noah, “Rewarding Regulatory Compliance: The Pursuit of Symmetry in Products Liability,” Georgetown Law Journal, 88, no.7 (2000): 2147, 2150-1.
5. W. Kip Viscusi, Steven R. Rowland, Howard L. Dorfman and Charles J. Walsh, “Deterring Inefficient Pharmaceutical Litigation: An Economic Rationale for the FDA Regulatory Compliance Defense,” Seton Hall Law Review 24, no. 3 (1994): 1437.
6. Steven P. Croley and William F. Funk, “The Federal Advisory Committee Act and Good Government,” Yale Journal on Regulation 14, no. 2 (1997): 451.
7. Consumer Product Safety Commission, “Substantial Product Hazard Reports,” Federal Register 71 (2006): 42028.
8. Robert L. Rabin, Federalism and the Tort System, 50 Rutgers L. Rev. 1, 8-9 (1997)
9. Securities and Exchange Commission, “Proposed Amendment to Rule 102(e) of the Commission’s Rules of Practice,” Federal Register 63 (1998): 33305.
10. Federal Trade Commission, “Telemarketing Sales Rule,” Federal Register 60 (1995): 43842.
11. Wendy Wagner, “Stubborn Information Problems and the Regulatory Benefits of Gun Litigation,” inSuing theGun Industry, ed. TimothyD. Lytton (Ann Arbor:University of Michigan Press, 2005), 271-280.
12. Daniel J. Gilveber and Anthony Robbins, “Public Health Versus Court-Sponsored Secrecy,” Law and Contemporary Problems 69, no. 3 (2006): 132.
13. David C. Vladeck, “Defending Courts: A Brief Rejoinder to Professors Fried and Rosenberg,” Seton Hall Law Review 31, no. 3 (2001): 631-2.
14. Wendy Wagner, “When All Else Fails: Regulating Risky Products through Tort Litigation,” Georgetown Law Journal 95, no. 3 (2007): 693.
15. Carl T. Bogus, “War on the Common Law: The Struggle at the Center of Products Liability,” Missouri Law Review 60, no. 1 (1995): 1-4.
16. Teresa M. Schwartz, “Prescription Products and the Proposed Restatement (Third),” Tennessee Law Review 61, no. 4 (1994): 1357-1386.
17. Vladeck, V. “Defending Courts,” 633-4.
18. Alex Berenson, “Disparity Emerges in Lilly Data on Schizophrenia Drug,” New York Times, December 21, 2006, C1.
19. Alex Berenson, “Eli Lilly Said to Play Down Risk of Top Pill,” New York Times, December 17, 2006, A1.
20. Alex Berenson, “Drug Files Show Maker Promoted Unapproved Use,” New York Times, December 18, 2006, A1.
21. Alex Berenson, “Blockbuster Drugs Are So Last Century,” New York Times, July 3, 2005, C1.
22. Alex Berenson, “Lilly Settles with 18,000 over Zyprexa,” New York Times, January 5, 2007, A1.
23. Gautam Naik, “Antipsychotic Drugs’ Link to Weight Gain Found,” Wall Street Journal, February 13, 2007, B1.
24. Andrew D. Goldstein, “Sealing and Revealing: Rethinking the Rules Governing Public Access to Information Generated through Litigation,” Chicago-Kent Law Review 81, no. 2 (2006): 375.
25. Nancy S. Marder, “Introduction to Secrecy in Litigation,” Chicago-Kent Law Review 81, no. 2 (2006): 305-313.
26. Laurie Kratky Dore, “Public Courts Versus Private Justice: It’s Time to Let Some Sun Shine in on Alternative Dispute Resolution,” Chicago-Kent Law Review 81, no. 2 (2006): 463.
27. Howard M. Erichson, “Court-Ordered Confidentiality in Discovery,” Chicago-Kent Law Review 81, no. 2 (2006): 357-8.
28. Environmental Protection Agency, “Perfluorooctanoic Acid (PFOA), Fluorinated Telomers; Request for Comment, Solicitation of Interested Parties for Enforceable Consent Agreement Development, and Notice of Public Meeting,” 68 Federal Register (2003): 18626-18628.
29. David Shaffer, “Former 3M Chemical is Widespread,” Minneapolis Star Tribune, August 15, 2004, A1.
30. Minnesota Public Radio, “Toxic Traces: Part 1: The Science” (2005) (available at http://news.minnesota.publicradio.org/projects/2005/02/toxictraces/).
31. Minnesota Public Radio, “Toxic Traces”; Michael Hawthorne, “InternalWarnings,” Columbus Dispatch, February 15, 2003, A1.
32. Environmental Protection Agency, “Perfluorooctanoic Acid (PFOA),” 18628.
33. Robert A. Bilott, “Request for Immediate Governmental Action/Regulation Relating to DuPont’s C-8 Releases in Wood County, West Virginia and Notice of Intent to Sue under the Federal CleanWater Act, Toxic Substances Control Act, and Resources Conservation and Recovery Act” (March 6, 2001): 5.
34. Environmental Protection Agency, “Perfluorooctanoic Acid (PFOA),” 18628.
35. Environmental Working Group, “PFCs: Global Contaminants: Part 3: PFCs Last Forever” (undated) (available at http://ewg.org/reports/pfcworld/part3.php).
36. Environmental Protection Agency, “Perfluorooctanoic Acid (PFOA),” 18629.
37. George L. Hegg, “Letter to Document Control Officer” (March 20, 1981).
38. Environmental Working Group, “PFCs: Global Contaminants: Part 4: PFC Health Concerns” (undated) (available at http://ewg.org/reports/pfcworld/part4.php).
39. KenWard, K. Jr., “Both Sides Hope for Answers on C8,” Charleston Gazette, March 6, 2005, B1.
40. Environmental Protection Agency, “Perfluorooctyl Sulfonates; Proposed Significant New Use Rule,” Federal Register 65 (2000): 62319- 62326.
41. R. J. Burger, “Memorandum to Supervision through Division Superintendents re C-8 Compounds” (March 31, 1981).
42. Jim Morris, “Coming Clean,” Mother Jones (September/October, 2001): 17.
43. Environmental Working Group, PFCs: Part 2: PFOA Is a Pervasive Pollutant in Human Blood, as are other PFCs” (undated) (available at http://www.ewg.org/reports/pfcworld/part2.php).
44. E. I. DuPont de Nemours, Co., “Washington Works Proposed Communication to Females.
45. Bruce W. Karrh, “Memorandum to Carl DeMartino re Epidemiology Study - C-8 (FC-143)” (April 6, 1981).
46. Bruce W. Karrh, “Memorandum to Carl DeMartino from re Epidemiology Study - C-8 (FC-143)” (April 2, 1981).Who Had Worked in Fluoropolymers Area” (April 9, 1981).
47. KenWard K Jr., “DuPont Proposed, Dropped’81 Study of C8, Birth Defects,” Charleston Sunday Gazette-Mail, July 3, 2005, A1.
48. Environmental Working Group, “DuPont Hid Teflon Pollution for Decades” (December 13, 2002) (available at http://www.ewg.org/issues/PFCs/20021113/20021213.php).
49. David Brown and Caroline E. Mayer, “3Mto Pare Scotchgard Products,”Washington Post, May 17, 2000, A1.
50. Terry Fiedler, “3M to Drop Scotchgard Lines,” Minneapolis Star-Tribune, May 17, 2000, A1.
51. Environmental Protection Agency, “Perfluorooctyl Sulfonates; Proposed Significant New Use Rule,” 62326.
52. Environmental Protection Agency, “Perfluorooctanoic Acid (PFOA),” 18628.
53. Juliet Eilperin, “EPA to Fine DuPont for Silence on Teflon Chemical,” Washington Post, July 9, 2004, A3.
54. Mike Lafferty, “Few in Village Seem Angry about Proposal in DuPont Suit,” Columbus Dispatch, September 11, 2004, B1.
55. Pat Phibbs, “DuPont to Pay $16.5 Million to Settle Alleged Violations of EPA Reporting Rules,” BNA Environment Reporter 36 (2005): 2581.
56. Julie Eilperin, “DuPont, EPA Settle Chemical Complaint,” Washington Post, December 15, 2005, D3.
57. Juliet Eilperin, “Harmful Teflon Chemical to be Eliminated by 2015,” Washington Post, January 26, 2006, A1.
58. Bebe Raupe, “Court Approves Class Action Settlement with Possible $340 Million DuPont Payout,” BNA Environment Reporter 38 (2005): 424-5.
59. Peter H. Schuck, “Why Regulating Guns through LitigationWon’tWork,” in Suing the Gun Industry, ed. Timothy D. Lytton (Ann Arbor: University of Michigan Press, 2005), 225-231.
60. Richard A. Epstein, Overdose (New Haven, CT, Yale University Press: 2006), 201.
61. Peter W. Huber, Liability: The Legal Revolution and Its Consequences (New York: Basic Books, 1988), 214.
62. Peter Huber, “Safety and the Second Best: The Hazards of Public Risk Management in the Courts,” Columbia Law Review 85, no. 2 (1985): 277-337.
63. “Regulation, Deregulation, Federalism, and Administrative Law: Agency Power to Preempt State Regulation,” University of Pittsburgh Law Review 46, no. 3 (1985), 607, 654-5.
64. W. Kip Viscusi, “Overview,” in Regulation through Litigation, ed. W. Kip Viscusi (Washington, D.C.: AEI Press, 2002), 2.
65. Robert L. Rabin, “Reassessing Regulatory Compliance,” Georgetown Law Journal 88, no. 7 (2000): 2049-2069.
66. Timothy D. Lytton, introduction to Suing the Gun Industry, ed. Timothy D. Lytton (Ann Arbor: University of Michigan Press, 2005), 1-31.
67. Margaret H. Clune, Stealth Tort Reform: How the Bush Administration’s Aggressive Use of the Preemption Doctrine Hurts Consumers (Washington, D.C.: Center for Progressive Regulation, 2004), 2-3.
68. Marcia Angell, The Truth about the Drug Companies (New York: Random House, 2005), 106-9.
69. Thomas O. McGarity and Wendy E. Wagner, Bending Science (Boston, MA: Harvard University Press, 2008), ch. 4.
70. Food and Drug Administration, “Requirements on Content and Format of Labeling for Human Prescription Drugs and Biological Products,” Federal Register, 71 (2006): 3922, 3934-6.